Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DFV890 and MAS825 in Coronary Heart Disease and CHIP
NCT06097663Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2024
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies, Bispecific Antibodies, Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of DFV890, MAS825 in coronary heart disease (CHD), clonal hematopoiesis of indeterminate potential (CHIP), sponsored by Novartis. Started Feb 2024; status: completed.
02
Drugs
DFV890MAS825
03
Conditions
coronary heart disease (CHD)clonal hematopoiesis of indeterminate potential (CHIP)
Beyond the preview
Go deeper on NCT06097663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06097663.